Frequently Asked Questions

Regenex Asia is a Malaysian biotechnology company that manufactures clinical-grade cell therapy products — stem cells (MSC), natural killer cells (NK), exosomes, CAR-T cells and CIK cells — in our cGMP-certified laboratory in Kuala Lumpur. We supply these products for direct patient treatment and as wholesale products for clinics, hospitals and research institutions.

We are primarily a manufacturer. Our cGMP-certified laboratory produces the cell therapy products. Treatments are administered either through our affiliated clinical network or through independent clinics and hospitals that source products from us. We also work directly with patients who come to Kuala Lumpur for treatment.

Our cGMP-certified facility is located in Kuala Lumpur, Malaysia. We operate under full approval from the Malaysian Ministry of Health (KKM) as a licensed cell therapy laboratory.

Six core differentiators: cGMP-certified manufacturing, Passage 2 cell quality, KKM regulatory approval, university research partnerships with University of Malaya and UKM, blockchain-verified supply chain traceability, and Syariah-compliant therapy options.

Read: Why Choose Regenex →

We manufacture and offer six cell therapy types: Mesenchymal Stem Cell (MSC) Therapy, Natural Killer (NK) Cell Therapy, Exosome Therapy, CAR-T Cell Therapy, Cytokine-Induced Killer (CIK) Cell Therapy, and PRP + Exosome Therapy. Each treats different conditions through different mechanisms.

View all treatments with comparison table →

Our therapies are applied across a wide range of conditions including anti-aging and longevity, osteoarthritis and joint pain, hair loss, skin rejuvenation, certain blood cancers (supportive immunotherapy), HIV and hepatitis B (immune reconstitution), diabetes, erectile dysfunction, chronic wounds, respiratory conditions and neurological support.

Try our Product Selector →

Stem cells (MSCs) are live cells that promote tissue repair and regeneration. NK cells are immune cells that target cancer and virus-infected cells. Exosomes are cell-free vesicles that deliver regenerative signals without live cells. Each works through a different mechanism and is suited to different conditions.

View the therapy comparison table →

Yes. Many patients benefit from combination protocols. Common combinations include MSC therapy with exosomes (for comprehensive anti-aging), PRP with exosomes (for hair and skin), and NK cells alongside conventional cancer treatment. Your physician will recommend the appropriate combination based on your condition.

No. Parkinson's disease is not a condition we currently treat. Our neurological applications focus on general neurodegeneration support, post-stroke recovery and age-related cognitive decline.

We offer supportive cell therapy for mild to moderate autism spectrum cases on an investigational basis. This is a sensitive and emerging application — we describe it as investigational, make no cure claims and require thorough medical assessment before proceeding.

Safety depends on the specific therapy and manufacturing quality. Our MSC, exosome and PRP + exosome therapies are generally well-tolerated with mild, temporary side effects. NK and CIK therapies carry a similarly favourable profile. CAR-T therapy carries more significant risks including cytokine release syndrome (CRS) and ICANS, which require specialist management. Every therapy's risk profile is discussed in detail during your consultation.

The most common side effects of MSC stem cell therapy are mild and temporary: low-grade fever, fatigue and localised discomfort at the injection site, typically resolving within 24–48 hours. Serious adverse events are rare with cGMP-manufactured, quality-tested allogeneic MSCs.

Read more about MSC safety →

Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are serious side effects associated with CAR-T cell therapy. Both range from mild to severe and require specialist management. These risks are specific to CAR-T therapy — they do not apply to MSC, exosome, PRP or NK cell treatments.

Read detailed CRS and ICANS information →

Every product comes with a Certificate of Analysis (CoA) documenting batch-specific test results: sterility, viability, endotoxin, mycoplasma, phenotype markers and functional potency assays. Our facility is cGMP-certified and KKM-approved with regular regulatory inspections. Our supply chain is blockchain-verified.

We do not publish pricing on our website. Treatment costs vary based on the therapy type, protocol, number of sessions and clinical complexity. After your consultation, our team provides a detailed treatment proposal with a full cost breakdown. We believe pricing should follow a thorough medical assessment — not precede it.

Cell therapy is not a one-size-fits-all service. The appropriate therapy, dosage, number of sessions and protocol depend on the individual patient's condition and goals. Publishing a single price would misrepresent the cost or encourage patients to choose based on price rather than clinical suitability. We provide transparent, detailed pricing after we understand your situation.

In most cases, cell therapy is not covered by standard medical insurance. Some international health insurance plans may offer partial coverage depending on the condition and jurisdiction. We recommend checking with your insurance provider. Our team can provide documentation your insurer may require.

Our treatment costs reflect Malaysian healthcare economics, which are fundamentally different from US or European pricing. CAR-T cell therapy in the US typically costs USD $350,000–$500,000 before hospital costs. We do not make direct price comparisons, but patients from Western markets consistently find treatment in Malaysia represents a meaningfully different cost proposition.

Generally, our patients fall into two categories: proactive patients (aged 35–60, healthy, seeking anti-aging or wellness optimisation) and condition-specific patients (seeking treatment for a diagnosed condition). Eligibility depends on the specific therapy, your condition severity, medical history and overall health. Our medical team assesses every patient individually.

Yes. We do not treat Parkinson's disease. We do not offer cell therapy as a replacement for emergency medical care or acute surgical conditions. Some therapies (particularly CAR-T) are limited to specific cancer indications. If your condition is outside our scope, we'll tell you honestly during consultation.

There is no strict age limit. Our therapies are most commonly sought by adults aged 35–60. For condition-specific treatments, eligibility is determined by the condition and medical status rather than age alone. Paediatric applications (such as CAR-T for childhood leukaemia) are assessed case-by-case.

Potentially, yes. Many patients address multiple concerns in a single treatment programme — for example, combining MSC therapy for joint health with exosome therapy for hair loss. Your physician will assess whether a multi-condition protocol is appropriate.

Yes. The majority of our patients are international, travelling to Kuala Lumpur from Japan, Indonesia, Singapore, Vietnam, the Middle East, Australia and beyond. We support international patients with visa guidance, airport transfers, hotel coordination and multilingual communication.

Full international patient information →

It depends on the therapy. PRP + Exosome: 1–3 days. MSC therapy: 2–5 days. NK/CIK therapy: 1–2 weeks. CAR-T therapy: approximately 6–8 weeks (including manufacturing and monitoring). Your timeline is confirmed during consultation.

Yes. Our team coordinates airport transfers, hotel accommodation, and provides multilingual support in English, Japanese, Bahasa Melayu, Bahasa Indonesia, Arabic, Vietnamese and Mandarin.

Most visitors can enter Malaysia on a standard tourist visa or visa-free entry for stays under 90 days. For longer stays (CAR-T therapy), a medical or social visit pass may be required. Our team provides visa guidance specific to your nationality and treatment timeline.

Malaysia is ranked number one globally for medical tourism, surpassing Thailand and South Korea. The country has internationally accredited hospitals, excellent healthcare infrastructure, a stable political environment and direct flights from all major Asian and Middle Eastern cities.

Our medical team reviews your submission within 1–2 business days. We may ask follow-up questions about your medical history. If appropriate, we arrange a consultation (remote or in-person). After consultation, you receive a detailed treatment proposal. There is no obligation to proceed at any stage.

Yes. We offer video consultations for international and local patients. Many patients complete their initial consultation remotely and travel to Kuala Lumpur only when they've decided to proceed.

PRP + Exosome: 60–90 minutes. Exosome injection: 30–60 minutes. MSC IV infusion: 30–60 minutes. NK/CIK infusions: 1–2 hours. CAR-T infusion: 30–60 minutes (but the entire process spans ~3 weeks from collection to infusion, plus 4+ weeks monitoring).

Minimal for most therapies. PRP + Exosome and exosome treatments typically have no downtime. MSC infusions may cause mild fatigue for 24–48 hours. NK/CIK may cause flu-like symptoms for 1–2 days. CAR-T requires close monitoring for 4+ weeks post-infusion.

It depends on the therapy and condition. PRP + Exosome typically involves 3–6 sessions. MSC therapy may involve one or multiple treatments. Anti-aging patients often return every 6–12 months for maintenance. Cancer immunotherapy protocols are determined by the oncologist.

Yes. We supply cGMP-manufactured products to clinics, hospitals and medical practices. Our B2B supply includes products with full Certificate of Analysis, protocol guidance, staff training and regulatory compliance documentation.

Learn more about clinic partnerships →

We offer flexible supply arrangements from single-treatment quantities to bulk clinic supply. Minimum order requirements depend on the product type and are discussed during onboarding.

Yes. We provide product handling, storage and clinical application training for clinic teams integrating Regenex products into their practice.

Yes. We have a distributor programme for organisations looking to distribute Regenex products. Current focus regions include Southeast Asia and the Middle East.

Distributor programme →

Yes. We partner with universities and pharmaceutical companies on clinical research. Our current collaborations with University of Malaya and UKM span multiple therapeutic areas.

Research partnerships →

No. We do not claim that our therapies cure any disease. All cell therapies are described as supportive, regenerative or investigational as appropriate. Patient outcomes vary. No specific results can be guaranteed.

Yes. Cell therapy is legal in Malaysia and operates within a regulatory framework overseen by the Ministry of Health (KKM). Regenex Asia holds full KKM approval as a licensed cell therapy laboratory.

Our products are manufactured to cGMP standards — the same quality framework required for FDA-approved products. However, Regenex products do not individually hold FDA approval, as we operate under Malaysian (KKM) regulatory authority. Some applications may be considered investigational in certain jurisdictions.

We comply with the Malaysian Personal Data Protection Act (PDPA) and maintain strict patient confidentiality. Medical information is stored securely, used only for treatment purposes and never shared without explicit consent.

Read our Privacy Policy →